The US Food and Drug Administration (FDA) has approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk for kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adult patients with chronic kidney disease ...
from Google Alert - health https://ift.tt/3ulsB65
via IFTTT
0 comments:
Post a Comment